Pages that link to "Q37291635"
Jump to navigation
Jump to search
The following pages link to Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells (Q37291635):
Displaying 50 items.
- Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4 (Q24294703) (← links)
- Cytokines in cancer drug resistance: Cues to new therapeutic strategies (Q26753299) (← links)
- Novel strategies to target the ubiquitin proteasome system in multiple myeloma (Q26773246) (← links)
- Modulatory effects of bortezomib on host immune cell functions (Q26795618) (← links)
- When ubiquitin meets NF-κB: a trove for anti-cancer drug development (Q26827754) (← links)
- Touch and go: nuclear proteolysis in the regulation of metabolic genes and cancer (Q28068146) (← links)
- Novel therapeutic strategies for multiple myeloma (Q28081590) (← links)
- Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma (Q28271286) (← links)
- Small compound 6-O-angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myeloma (Q28478936) (← links)
- Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells (Q28481321) (← links)
- Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib (Q28547243) (← links)
- Tyrosine phosphorylation allows integration of multiple signaling inputs by IKKβ (Q28660962) (← links)
- Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma (Q28742668) (← links)
- Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines. (Q31028788) (← links)
- A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma (Q33407672) (← links)
- Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve. (Q33617012) (← links)
- Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia (Q33732419) (← links)
- A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells (Q33834752) (← links)
- Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation (Q33855223) (← links)
- The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo (Q33896749) (← links)
- MCPIP1 contributes to the toxicity of proteasome inhibitor MG-132 in HeLa cells by the inhibition of NF-κB (Q34038263) (← links)
- Targeting cullin-RING ligases for cancer treatment: rationales, advances and therapeutic implications (Q34043821) (← links)
- A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy (Q34044757) (← links)
- Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia (Q34048276) (← links)
- A review of the application of inflammatory biomarkers in epidemiologic cancer research (Q34135803) (← links)
- The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. (Q34235332) (← links)
- Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation (Q34542087) (← links)
- Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era (Q34568868) (← links)
- Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity (Q34576976) (← links)
- The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma (Q34707136) (← links)
- Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway (Q34786865) (← links)
- Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. (Q34788381) (← links)
- Polymorphisms of nuclear factor- B family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens (Q34890498) (← links)
- Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma (Q34924231) (← links)
- Proteasome inhibitors in cancer therapy (Q34939959) (← links)
- Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells (Q35005510) (← links)
- Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma (Q35054403) (← links)
- NF-κB addiction and its role in cancer: ‘one size does not fit all’ (Q35120893) (← links)
- Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma (Q35146262) (← links)
- In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells (Q35167162) (← links)
- Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy (Q35408665) (← links)
- NF-κB signaling mediates acquired resistance after PARP inhibition (Q35551882) (← links)
- Curcumin and its analogue induce apoptosis in leukemia cells and have additive effects with bortezomib in cellular and xenograft models (Q35667904) (← links)
- Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells (Q35786902) (← links)
- Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy (Q35832168) (← links)
- Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives (Q35836881) (← links)
- Microscale functional cytomics for studying hematologic cancers (Q35849287) (← links)
- Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities (Q35849327) (← links)
- Autophagy promotes intracellular degradation of type I collagen induced by transforming growth factor (TGF)-β1. (Q35874334) (← links)
- The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells (Q35889653) (← links)